Analyst Price Targets — BCAX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 11, 2026 9:42 pm | Richard Law | Goldman Sachs | $14.00 | $14.80 | TheFly | Bicara moved to Neutral from Early-Stage Biotech at Goldman Sachs |
| January 8, 2026 12:03 pm | — | BTIG | $28.00 | $17.17 | TheFly | Bicara Therapeutics initiated with a Buy at BTIG |
| December 17, 2025 9:10 pm | Joseph Catanzaro | Mizuho Securities | $18.00 | $17.98 | TheFly | Bicara Therapeutics initiated with a Neutral at Mizuho |
| August 22, 2025 10:44 am | Robert Burns | H.C. Wainwright | $40.00 | $11.84 | TheFly | Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright |
| May 23, 2025 4:54 pm | Eva Fortea Verdejo | Wells Fargo | $8.00 | $9.27 | TheFly | Bicara Therapeutics upgraded to Equal Weight from Underweight at Wells Fargo |
| March 27, 2025 5:58 pm | — | Stifel Nicolaus | $48.00 | $13.40 | TheFly | Bicara Therapeutics price target raised to $48 from $47 at Stifel |
| October 8, 2024 5:56 am | Judah Frommer | Morgan Stanley | $35.00 | $24.45 | TheFly | Bicara Therapeutics initiated with an Overweight at Morgan Stanley |
Latest News for BCAX
Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $21.63 and last traded at $20.85, with a volume of 552051 shares trading hands. The stock had previously closed at $21.47. Analyst Ratings Changes A number of equities analysts
BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on April 1, 2026 to one new employee under Bicara's 2026 Inducement Plan as a material inducement to employment.
Shares of Bicara Therapeutics Inc. (NASDAQ: BCAX - Get Free Report) reached a new 52-week high on Wednesday after The Goldman Sachs Group raised their price target on the stock from $14.00 to $16.00. The Goldman Sachs Group currently has a neutral rating on the stock. Bicara Therapeutics traded as high as $21.05 and last traded
The average of price targets set by Wall Street analysts indicates a potential upside of 54.9% in Bicara Therapeutics Inc. (BCAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bicara Therapeutics Inc. maintains a Buy rating, driven by progress in its pivotal phase 3 FORTIFI-HN01 study for 1st-line R/M HPV-negative HNSCC. BCAX's ficerafusp alfa plus KEYTRUDA achieved a 12-month OS of 61% and a confirmed ORR of 54% in phase 1/1b, supporting continued development. Key upcoming catalysts for BCAX include phase 3 interim data in mid-2027 and long-term phase 1b follow-up at ASCO 2026, with…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BCAX.
U.S. House Trading
No House trades found for BCAX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.